Therapeutic drug monitoring

Current Opinion in Anaesthesiology

Volumn 15, Issue 6, 2002, Pages 687-692

  Shenfield, Gillian M ^a   Morris, Raymond G ^b,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Antimetabolites; HIV AIDS; Immunosuppressants; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ANTIMETABOLITE; ANTIRETROVIRUS AGENT; CYCLOSPORIN; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANALYTIC METHOD; ASTHMA; CLINICAL PRACTICE; COMPUTER PROGRAM; CONCENTRATION (PARAMETERS); DEPRESSION; DRUG DETERMINATION; DRUG MECHANISM; DRUG MONITORING; EPILEPSY; FORECASTING; HEART ARRHYTHMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; ORGAN TRANSPLANTATION; PATIENT CARE; POPULATION DYNAMICS; PRIORITY JOURNAL; REVIEW; TOXICITY; TREATMENT OUTCOME;

EID: 0036931982     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200212000-00014     Document Type: Review

References (49)

1. Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52 (Suppl):5-10. A very clear and comprehensive account of the principles of TDM as opposed to 'measurement'.
2. Eadie MJ, Therapeutic drug monitoring - Antiepileptic drugs. Br J Clin Pharmacol 2001; 52(Suppl):11-20. An excellent review covering rationale, outcomes and cost effectiveness.
3. Campbell TJ, Williams KM. Therapeutic drug monitoring: Antiarrhythmic drugs. Br J Clin Pharmacol 2001; 52(Suppl):21-34. A lucid account of the topic with special emphasis on problem areas, e.g. digoxin, perhexiline.
4. Begg EJ, Barclay ML, Kirkpatrick CM The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001; 52(Suppl):35-43. A very good overview with critical appraisal of controversial topics and suggested practical solutions.
5. Mitchell PB. Therapeutic drug monitoring of psychotropic medications. Br J Clin Pharmacol 2001; 52(Suppl):45-54. A good overview particularly of classical antidepressants.
6. Steimer W, Müller B, Leucht S, Kissling W, Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 2001; 308:33-41.
7. Holt DW, Armstrong VW, Griesmacher A, et al. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group in immunosuppressive drug monitoring. Ther Drug Monit 2002; 24:59-67. This study describes work in progress updating consensus guidelines for the four major immunosuppressant drugs.
8. Armstrong WV, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus and azathioprine. Clin Biochem 2001; 34:9-16. A good overview of recent expert opinions.
9. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise consensus conference on cyclosporin and tacrolimus. Clin Biochem 1998; 31:309-316.
10. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: Review of current algorithms. Ther Drug Monit 2001; 23:100-114.
11. Johnston A, Holt DW. Immunosuppressant drugs - The role of therapeutic drug monitoring. Br J Clin Pharmacol 2001; 52(Suppl):61-73. A very good comprehensive review covering current perspectives and controversies.
12. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24:330-350. An outstanding, extremely well referenced review of TDM of immunosuppressants for transplant patients.
13. Morris RG, Lam AK. Cyclosporin monitoring in Australasia - A survey of laboratory practices in 2000. Ther Drug Monit 2002; 24:471-478.
14. Morris RG, Ilett KF, Tett SE, et al. Cyclosporin monitoring in Australasia - Update of consensus guidelines 2002. Ther Drug Monit 2002; in press.
15. McDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22 (Suppl. B):B101-B121.
16. Cogill JL, Taylor PJ, Westley IS, et al. Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. Clin Chem 1998; 44:1942-1946.
17. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant recipients. Clin Biochem 2001;34:17-22. A very good summary of TDM for mycophenalate mofetil.
18. Weber LT, Shipkova M, Armstrong WN, et al. Comparison of the EMIT immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in paediatric renal-transplant: Recipients on mycophenolate mofetil therapy. Clin Chem 2002; 48:517-525.
19. Back DJ, Khoo SH, Gibbons SE, Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001; 52(Suppl):89-96. An excellent review of the mechanisms of drug action and the scientific underpinning of TDM in HIV/AIDS.
20. Heeswijk RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit 2002; 24:323-331. A very useful, up to date summary of current key issues and controversies.
21. Hoetelmans RM. Therapeutic drug monitoring in HIV disease. J HIV Ther 2001; 6:65-67. An editorial providing a clear summary of all the relevant and controversial issues.
22. Khoo SH, Gibbons SE, Back DJ. Therapeutic drug monitoring as a tool in treating HIV infection. AIDS 2001; 15 (Suppl. 5):S171-S181. A very good clinically orientated overview with a realistic assessment of the benefits and weaknesses.
23. Dasgupta A, Okhyysen PC, Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit 2001; 23:591-605. A comprehensive review of drug interactions with all groups of antiretroviral agents.
24. Rainey PM. HIV Drug interactions: The good, the bad and the other. Ther Drug Monit 2002; 24:26-31.
25. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J AIDS 2002; 29(Suppl):11-18. A review of PIs and the mechanisms by which they may interact with other drugs.
26. Luber AD, Gunawan S, Lee S. Serum and plasma drug levels of amprenavir display limited inter- and intra-patient variability. AIDS 2000; 14 (Suppl. 4):92.
27. Langmann P, Zilly M, Weissbrich B, et al. Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection 2002; 30:13-16. A retrospective study demonstrating that TDM can identify non-compliance as a cause of therapeutic failure.
28. John L, Marra F, Ensom MH. Role of therapeutic drug monitoring for protease inhibitors. Ann Pharmacother 2001; 35:745-754.
29. Veldkamp AI. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1 infected individuals. AIDS 2001; 15:1089-1095.
30. trough inhibitory quotient predicts virologic response to ABT-378/ritonavir (ABT-378/R) therapy in treatment-experienced patients [Abstract PLg.4]. AIDS 2000; 14 (Suppl. 4):S12.
31. Clevenbergh P, Durant J, Garraffo R. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentre randomized controlled trial: 12 Weeks' results. In: 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001 [Abstract 260B].
32. Heeswijk RP, Stuart JW, Burger DM, et al. Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study. Br J Clin Pharmacol 2002; 53:211-214.
33. van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet 2002; 2:93-102.
34. Angel JB, Khaliq Y, Monpetit ML, et al. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS 2001; 15:417-419.
35. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: Current status and future directions. AIDS 2002; 16 (Suppl. 1):S5-S37. A very useful report of an expert consensus meeting that produced position statements regarding current status and future applications of TDM for antiretroviral therapy.
36. Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br J Clin Pharmacol 2001; 52(Suppl):75-87. An excellent comprehensive review providing full details and references for the rationale of TDM and a clear explanation of the role of TPMT.
37. Lennard L, Lilleymans JS, Van Loon JA, Weinshilbourn RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336:226-229.
38. Nielson OH, Vainer B, Rask-Madsen J. Review article: The treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15:1699-1708.
39. Holford NH. Target concentration intervention: Beyond Y2K. Br J Clin Pharmacol 2001; 52(Suppl):55-59. A provocative review, challenging many current concepts of TDM but suggesting a rational, practical way forward.
40. Perucca E. Marketed new antiepileptic drugs: Are they better than old-generation agents? Ther Drug Monit 2002; 24:74-80. A good update of the new antiepileptic agents.
41. Uijtendaal EV, Rademaker CM, Schobben AF, et al. Once-daily versus multiple-daily gentamicin in infants and children. Ther Drug Monit 2001; 23:506-513.
42. Pons GTJ, Dimet J, Merle Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit 2002; 24:9-14.
43. Chan V, Morris RG, Ilett KF, Tett SE. Population pharmacokinetics of lamotrigine. Ther Drug Monit 2001; 23:630-635.
44. Tréluyer JM, Merlé Y, Tonnelier S, et al. Nonparametic population pharmacokinetic analysis of amikacin in neonates, infants and children. Antimicrob Agents Chemother 2002; 46:1381-1387.
45. Hussein R, Charles BG, Morris RG, Rasiah RL. Population pharmacokinetics of perhexiline from very sparse routine monitoring data. Ther Drug Monit 2001; 23:636-643.
46. Reith DM, Hooper WD, Parke J, Charles B. Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents and adults. J Pharmacokinet Pharmacodyn 2001; 28:79-92.
47. Nguyen L, Tranchant B, Puozzo C, Variol P. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase 1 clinical trials. Br J Clin Pharmacol 2001; 53:459-468.
48. Mould DR, Holford HG, Schellens JH, et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin Pharmacol Ther 2002; 71:334-348.
49. Huitema AD, Mathôt RA, Tibben MM, et al. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen. Ther Drug Monit 2001; 23:650-657.